Safety and Efficacy of Allogeneic Lung Spheroid Cells in a Mismatched Rat Model of Pulmonary Fibrosis.

Journal Article (Journal Article)

Idiopathic pulmonary fibrosis is a devastating interstitial lung disease characterized by the relentless deposition of extracellular matrix causing lung distortions and dysfunctions. The prognosis after detection is merely 3-5 years and the only two Food and Drug Administration-approved drugs treat the symptoms, not the disease, and have numerous side effects. Stem cell therapy is a promising treatment strategy for pulmonary fibrosis. Current animal and clinical studies focus on the use of adipose or bone marrow-derived mesenchymal stem cells. We, instead, have established adult lung spheroid cells (LSCs) as an intrinsic source of therapeutic lung stem cells. In the present study, we compared the efficacy and safety of syngeneic and allogeneic LSCs in immuno-competent rats with bleomycin-induced pulmonary inflammation in an effort to mitigate fibrosis development. We found that infusion of allogeneic LSCs reduces the progression of inflammation and fibrotic manifestation and preserves epithelial and endothelial health without eliciting significant immune rejection. Our study sheds light on potential future developments of LSCs as an allogeneic cell therapy for humans with pulmonary fibrosis. Stem Cells Translational Medicine 2017;9:1905-1916.

Full Text

Duke Authors

Cited Authors

  • Cores, J; Hensley, MT; Kinlaw, K; Rikard, SM; Dinh, P-U; Paudel, D; Tang, J; Vandergriff, AC; Allen, TA; Li, Y; Liu, J; Niu, B; Chi, Y; Caranasos, T; Lobo, LJ; Cheng, K

Published Date

  • October 2017

Published In

Volume / Issue

  • 6 / 10

Start / End Page

  • 1905 - 1916

PubMed ID

  • 28783251

Pubmed Central ID

  • PMC6430052

Electronic International Standard Serial Number (EISSN)

  • 2157-6580

International Standard Serial Number (ISSN)

  • 2157-6564

Digital Object Identifier (DOI)

  • 10.1002/sctm.16-0374

Language

  • eng